In-Principle Approval

Name of Company*Neogen Chemicals Limited
ISIN*INE136S01016
Corporate Identity Number (CIN) of the Listed Entity*L24200MH1989PLC050919
Permanent Account Number (PAN)*AAACN5836E
BSE Scrip code*542665
NSE SymbolNEOGEN
MSEI SymbolNOTLISTED
Board resolution approving the issue of specified securities *07-03-2026
Object of the Issue (As per Notice/offer document) *
Category of Allottee*Promoter

Detials of security

Security TypeNumber of securitiesAmount to be raised ( Rs in Lakhs)Relavent DateMinimum Issue Price (per security)Terms of Payment in % (100/25/other specify)
DDMMYYYY
Equity Shares100000016100270220261610100
Total amount to be raised ( Rs in Lakhs)16100
Consideration*Cash
Description of other consideration
Details of allottes*
Date Of Submission24-03-2026
NotesMr. Haridas Kanani and Mrs. Beena Haridas Kanani, the members of promoter and promoter group of the Company have done inter se transfer of equity shares by way of gift to their respective Trust on 31-12-2025 pursuant to an exemption order passed by SEBI on December 30, 2025 bearing reference number WTM/ KCV/ CFD/ 17/2025-26 and the said inter-se transfers was during the 90 trading days preceding the Relevant Date and hence the proposed allottee Cadamba Solutions Private Limited who is also a promoter group member of the Company w.e.f. 15-12-2025, has made an application to SEBI pursuant to regulation 300 of SEBI ICDR regulations seeking exemption from strict application of regulation 159 read with explanation thereof of the SEBI ICDR regulations.The allotment of the said equity shares shall be subject to the Order being passed by SEBI in this matter.



Details of allottes

Sr.Name of allottesSecurity typeNo of securities to be allotted
1Cadamba Solutions Private LimitedEquity Shares1000000



Object of the Issue

Sr.ObjectDetails of the object
1Investment in Neogen Ionics Limited -a wholly owned subsidiary of Neogen Chemicals LimitedAmount in Rs. In Crores: 80 - 100, Utilisation timeline: Up to 90 days, There may be variation not exceeding +/- 10% in the estimated amounts specified against each of the objects.
2Meeting Working capital requirementsAmount in Rs. In Crores: 21 - 41, Utilisation timeline: Up to 90 days, There may be variation not exceeding +/- 10% in the estimated amounts specified against each of the objects.
3General corporate purposesAmount in Rs. In Crores: 40, Utilisation timeline: Up to 90 days, There may be variation not exceeding +/- 10% in th e estimated amounts specified against each of the objects. The amount utilized for general corporate purpose shall not exceed 25% of the Gross Proceeds. Further, the fund requirements are based on internal management estimates and have not been appraised by any bank, financial institution or any other external agency. They are based on current circumstances of our business. The Company may have to revise its estimates from time to time on account of various factors beyond its control, such as financial, market and sectoral conditions, competitive environment, business performance and strategy and interest or exchange rate fluctuations. Consequently, the funding requirements of our Company and deployment schedules are subject to revision in the future at the discretion of the management. Pending utilization of the proceeds from the Preferential Issue, the Company shall invest such proceeds in money market instruments including money market mutual funds, deposits in scheduled commercial banks or any other investment as permitted under applicable laws.